What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipation Treatment Market

What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the accessibility of effective medication for OIC, a surge in the use of opioids, and a rising occurrence of digestive system disorders.

Expectations indicate a robust expansion in the market size for opioid-induced constipation treatment in the coming few years, hitting a growth volume of $2.47 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. This burgeoning growth in the projected period is largely due to various factors such as expedited drug approval processes, the escalated use of opioid analgesic prescriptions, increased R&D expenditure for new treatments, and a rise in biologics development. Patient education and awareness, the introduction of new targeted therapies, non-pharmacological treatments, biotechnological advancements, and augmented investment are the significant trends expected to dominate the forecast period.

What Factors Are Fueling Growth in the Opioid-Induced Constipation Treatment Market?
The escalating use of opioids for the treatment of both cancer-related and non-cancer-related discomfort is anticipated to fuel the growth of the market for opioid-induced constipation remedies in the future. Cancer pain is linked to the distress that results from the disease and the treatments it involves, whereas non-cancer pain is brought about by conditions not associated with cancer. The necessity to manage moderate to severe discomfort effectively, taken into consideration the severity and duration of pain, patient's response to alternate treatments, and the ultimate objective to enhance the quality of life while reducing the possibilities of dependency and adverse effects, is driving the use of opioids for both types of pain. By aiding in the alleviation of constipation resulting from opioid usage, opioid-induced constipation (OIC) treatments provide further comfort to patients dealing with cancer or non-cancer pain, promoting adherence to pain management plans and enhancing the quality of life without sacrificing pain relief. For example, the Government of Canada, a Canada-based federal administration, reported in May 2021 that chronic pain could affect up to 8.3 million Canadians by 2025 and is projected to impact up to 9.0 million by 2030. Therefore, the increasing use of opioids for the management of cancer and non-cancer pain is bolstering the growth of the opioid-induced constipation treatment market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Businesses Are at the Forefront of Opioid-Induced Constipation Treatment Market Development?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

What Are the Latest Innovations in the Opioid-Induced Constipation Treatment Market?
Prominent organizations in the opioid-induced constipation treatment market are utilizing strategic collaborations to create innovative drugs. These alliances enable companies dealing with opioid-induced constipation treatment to merge resources and knowledge, boost research and development, broaden market outreach, and speed up product dissemination, consequently pushing innovation and growth in the industry. For instance, in November 2022, Kyowa Kirin Co. Ltd, a biotechnology firm based in Japan, established a collaboration with Grünenthal GmbH, a Germany-based pharmaceutical company to amalgamate solutions for patients. Through this collaboration, their intention is to amplify the growth and global accessibility of a collection of groundbreaking pain management medicines, including therapies for opioid-induced constipation, advanced cancer pain, and osteoporosis.

How Is the Opioid-Induced Constipation Treatment Market Segmented?
The opioid-induced constipation treatment market covered in this report is segmented -

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Where Is the Opioid-Induced Constipation Treatment Market Growth Most Prominent?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Opioid-Induced Constipation Treatment Global Market Report?

- Market Size Analysis: Analyze the Opioid-Induced Constipation Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Opioid-Induced Constipation Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Opioid-Induced Constipation Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Opioid-Induced Constipation Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.